Received Sep 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLUZONE) | SANOFI PASTEUR | 1 | UT8792LA | OT |
fluzone administered while mother was pregnant with no reported adverse event; Initial information received on 08-Sep-2025 regarding an unsolicited valid non-serious case received from a nurse. This case involves a 32 years old female patient who was exposed to vaccine influenza USP trival A-B subvirion NO preservative vaccine [fluzone] in context of fluzone administered while mother was pregnant with no reported adverse event. Data regarding this pregnancy were received prospectively, i.e. before pregnancy outcome was known. The reported fluzone administered while mother was pregnant with no reported adverse event occurred at 7 weeks of pregnancy and the patient was exposed to INfLUENZA USP trival A-B subvirion NO preservative vaccine at 7 weeks of pregnancy, during first pregnancy trimester for influenza USP trival A-B subvirion NO preservative vaccine. The date of last menstrual period was reported as 01-Aug-2025. The estimated due date is 01-May-2026. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. The patient had unknown previous pregnancy/ies. On 08-Sep-2025, the pregnant patient received a Dose 1 of suspect influenza USP trival A-B subvirion NO preservative vaccine Suspension for injection (Unknown strength and expiry date) with lot UT8792LA via intramuscular route in unknown administration site for prophylactic vaccination (Immunisation) with no reported adverse event (exposure during pregnancy) (latency same day) There were no information Relevant prenatal testing after exposure. Action taken was not applicable. Additionally, at time of reporting, the pregnancy is still ongoing.